Current Report Filing (8-k)
September 09 2020 - 8:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 8, 2020
Kewaunee Scientific Corporation
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
0-5286
|
|
38-0715562
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
2700 West Front Street
Statesville, North Carolina
|
|
28677
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: 704-873-7202
N/A
(Former name or former address, if changed since last report.)
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, $2.50 par value
|
|
KEQU
|
|
NASDAQ Global Market
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 2.02
|
Results of Operations and Financial Condition
|
On September 8, 2020, Kewaunee Scientific Corporation (the Company) issued a press release announcing its financial results for the first
quarter, ended July 31, 2020, of fiscal year 2021. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The Company is making reference to non-GAAP financial information in the press release. A reconciliation of these non-GAAP financial measures is contained in
the attached press release.
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits:
In accordance with General Instruction B.2 of Form 8-K, the information in this
Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the
liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific
reference in such filing.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Registrant)
|
|
|
|
|
|
|
Kewaunee Scientific Corporation
|
|
|
|
|
Date: September 9, 2020
|
|
|
|
|
|
/s/ Donald T. Gardner III
|
|
|
|
|
|
|
Donald T. Gardner III
|
|
|
|
|
|
|
Vice President, Finance and
Chief Financial Officer
|
Kewaunee Scientific (NASDAQ:KEQU)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kewaunee Scientific (NASDAQ:KEQU)
Historical Stock Chart
From Apr 2023 to Apr 2024